Intrinsiqq
OncoZenge AB logo

OncoZenge AB Quality Score

ONCOZ.XSTO

Compare
Quality0

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-0.1x

Negative earnings, no valuation support

Cash Flow Multiple
0/100
-1.7x

Negative FCF, no valuation support

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
0/100
19.9%

Heavy dilution above 5%

Capital Structure
0/100
kr 4M

Positive debt with no FCF to service it

2022
kr 29.0M
kr 0.00
2023
kr 13.0M
kr 0.00
2024
kr 4.00M
kr 0.00
2025
kr 4.00M
kr 8.00M
CashDebt
Return on Capital
0/100
-96.2%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

OncoZenge AB (ONCOZ.XSTO) quality: score, margins and returns

OncoZenge AB (ONCOZ.XSTO) scores 0/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 4 metrics each scored 0 to 100, on -439.8% operating margins and -96.2% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is OncoZenge AB (ONCOZ.XSTO) a high-quality business?+

OncoZenge AB scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -439.8% operating margin and a -96.2% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does OncoZenge AB's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from ONCOZ.XSTO's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where OncoZenge AB scores well and where it falls behind.

What is OncoZenge AB's return on invested capital (ROIC)?+

OncoZenge AB earns about -96.2% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to ONCOZ.XSTO's margins and growth on this scorecard to judge durability.

How profitable is OncoZenge AB?+

OncoZenge AB runs an operating margin of about -439.8% and a net margin of about -452.0%. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.

More on ONCOZ.XSTO: Overview · DCF valuation · Dividend safety · Financials
How the market compares: US profitability statistics

Peers

Biotechnology · Pick stocks to compare with ONCOZ.XSTO

CompareIntrinsic value
NEWBRY.XSTONewbury Pharmaceuticals AB
€0.11+0.91%40
NXTCL.XSTONextCell Pharma AB
€0.01+18.52%50
KDEV.XSTOKDventures AB
kr 0.14+6.06%25
BIOSGN.XSTOBiosergen AB
No recent price20
HEART.XSTOScandinavian Real Heart AB
€1.28-0.39%10
2CUREX.XSTO2cureX AB
No recent price10
APOTEA.XSTOApotea AB
€9.00-0.94%71
XVIVO.XSTOXVIVO Perfusion AB
kr 197.15+1.00%44

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing ONCOZ.XSTO

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.